Drug intelligence / Profile preview

Emoclot

Development stage: Phase 4
Lead developer: Kedrion
Modality: Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

**Emoclot** is a Kedrion plasma-derived human coagulation factor VIII concentrate that contains von Willebrand factor. It is administered intravenously as replacement therapy to raise circulating factor VIII activity, control or prevent bleeding in congenital hemophilia A, and has been studied for immune-tolerance induction in hemophilia A patients with factor VIII inhibitors. ([rxreasoner.com](https://www.rxreasoner.com/monographs/emoclot))

Brand names: Emoclot

Targets

Coagulation Factor IXaBB-031 (Von Willebrand factor)Phospholipid membrane surface

Beyond the preview

Go deeper on Emoclot.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emoclot.

Explore the full profile